Abstract
Carbamazepine (25 mg/kg body weight) was administered intraperitoneally to adult male Wistar rats for 45 days and norepinephrine (NE), dopamine (DA) and serotonin (5-HT) levels were simultaneously assayed in discrete brain regions by high performance liquid chromatographic (HPLC) method. Experimental rats displayed no behavioral abnormalities. Body and brain weights were not significantly different from control group of rats. After exposure it was observed that norepinephrine levels were elevated in motor cortex (P<0.01) and cerebellum (P<0.05), while dopamine levels were decreased in these two regions (P<0.001, P<0.05). However, dopamine levels were increased in hippocampus (P<0.01). Serotonin levels were significantly decreased in motor cortex (P<0.001) and hypothalamus (P<0.001) but increased in striatum-accumbens (P<0.001) and brainstem (P<0.001). These results suggest that carbamazepine may mediate its anticonvulsant effect by differential alterations of monoamine levels in discrete brain regions particularly in motor cortex and cerebellum.
Similar content being viewed by others
References
Simonsen, J., Zander Olsen, P., Kuhl, V., Lund, M., and Wendelboe, J. 1976. A comparative controlled study between carbamazepine and diphenyl hydantoin in psychomotor epilepsy. Epilepsia 17:169–176.
Troupin, A., Ojemann, L. M., Halpern, L., Dodrill, C., Wilkur, R., Friel, P., and Feigl, P. 1977. Carbamazepine — A double blind comparison with phenytoin. Neurology 27:511–519.
McLean, M. J., Taylor, C. P., and Macdonald, R. L. 1984. Phenytoin and carbamazepine limit sustained high frequency repetitive firing of action potentials of hippocampal neurons in cell culture and tissue slices. Soc. Neurosci. Abst. 10:873.
McLean, M. J., and Macdonald, R. L. 1986. Carbamazepine and 10, 11-epoxy carbamazepine produce use and voltage dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Therap. 228:727–738.
Jullien, R. M., and Hollister, R. P. 1975. Carbamazepine: Mechanism of action. Adv. Neurol. 11:263–277.
Rasmussen, P., and Rushede, J. 1970. Facial pain treated with carbamazepine Tegretol. Acta Neurol. Scand. 46:385–408.
Hernandez-Peon, R. 1964. Anticonvulsant action of G 32883. Third Proc. Int. Neuropsychopharmacologicum 3:303–311.
Skeritt, J. H., Davies, L. P., and Johnston, G. A. R. 1983. Interactions of the anticonvulsant carbamazepine with adenosine receptors; Neurochemical studies. Epilepsia 24:642–643.
Marangos, P. J., Post R. M., Patel, J., Zander, K., Parma, A., and Weiss, S. 1983. Specific and potent interactions of carbamazepine with brain adenosine receptors. Eur. J. Pharmacol. 93:175–182.
Schlichter, W., Bristow, M. F., and Schultz, R. S. 1986. Seizures occuring during intensive chlorpromazine therapy. Can. Med. Assoc. J. 74:364–366.
Azzaro, A. J., Wenger, G. R., Craig, C. R., and Stitzel, R. E. 1972. Reserpine induced alterations in brain amines and their relationship to changes in the incidence of minimal electro-shock seizures in mice. J. Pharmacol. Exp. Ther. 180:558–568.
Kilian, M., and Frey, H. H. 1973. Central monoamines and convulsive thresholds in mice and rats. Neuropharmacology 12:681–692.
Mohr, E., and Corcoran, M. E. 1981. Depletion of noradrenaline and amygdaloid kindling. Exp. Neurol. 72:507–511.
Hiramatsu, M., Fujimoto, N., and Mori, A. 1982. Catecholamine level in cerebrospinal fluid of epileptics. Neurochem. Res. 7:157–171.
Mori, A., Hiramatsu, M., Namba, S., Nishimoto, A., Ohnoto, J., Mayanagi, Y., and Sakura, T. 1987. Decreased dopamine levels in the epileptic focus. Res. Commun. Chem. Pathol. Pharmacol. 56:157–164.
Pintor, M., Pocotte, S., and Mefford, I. 1988. Indoles, catechols and tyrosine hydroxylase in the human epileptic cortex. Soc. Neurosci. Abstr. 14:1032.
Wada, J. A., Balzamo, E., Meldrum, B. S., and Naquet, R. 1972. Behavioral and electrographic effects ofl-5-hydroxytryptophan andD,L-para-chlorophenylalanine in epileptic Senegalese baboon Papio papio. Electroencephalogr. Clin. Neurophysiol. 3:520–526.
Meldrum, B. S., Turski, L., Schwarz, M., Cruezuar, S. J., Sontag, K. H. 1986. Anticonvulsant action of 1, 3-dimethyl 5-aminoadamantane: pharmacological studies in rodents and baboon, Papio papio. Naunyn. Schmiedebergs. Arch. Pharmacol. 332:93–97.
Westerink, B. H. C., Lejeune, B., Korf, J., and Van Pragg, H. M. 1977. On the significance of regional dopamine metabolism in the rat brain for the classification of centrally acting drugs. Eur. J. Pharmacol. 42:179–190.
Quattrone, A., Crunelli, V., and Samanin, R. 1978. Seizure Susceptibility and anticonvulsant activity of carbamazepine, diphenyl hydantoin and phenobarbital in rats with selective depletion of brain monamines. Neuropharmacology 17:643–647.
Purdy, R. E., Julien, R. M., Fairhurst, A. S., and Terry, M. D. 1977. Effect of carbamazepine on in vitro uptake and release or norepinephrine in adrenergic nerves of rabbit aorta and in whole brain synaptosomes. Epilepsia 18:251–257.
Quattrone, A., Annunziato, L., Aguglia, U., and Preziosi, P. 1981. Carbamazepine, phenytoin and phenobarbitone do not influence brain catecholamine uptake, invivo in male rats. Arch. Int. Pharmacodyn. Ther. 252:180–185.
Lindgren, S., Anden, N. E., and Anden, M. G. 1982. A flourometric method for determination of GABA in tissues following cation exchange chromatography and condensation with O-phthalaldehyde. J. Neural. Transm. 55:243–252.
Murai, S., Saito, H., Masuda, Y., and Itoh, T. 1988. Rapid determination of norepinephrine, dopamine, serotonin, their precursor aminoacids and related metabolites in discrete brain areas of mice within ten minutes by HPLC with electrochemical detection. J. Neurochem. 50:473–479.
Farhali-Hassan, Assael, B. M., Bossi, L., Garathini, S., Gerna, M., Gomeni, R., and Morselli, P. L. 1976. Carbamazepine pharmacokinetics in young adult and pregnant rats. Relation to pharmacological effects. Arch. Int. Pharmacodyn. Ther. 220:125–139.
Quattrone, A., and Samanin, R. 1977. Decreased anticonvulsant activity of carbamazepine in 6-hydroxy dopamine treated rats. Eur. J. Pharmacol. 41:333–336.
Waldmeier, P. C., Baumann, P. A., Fehr, B., De Herdt, P., and Maitre, L. 1984. Carbamazepine decreases catecholamine turnover in the rat brain. J. Pharmacol. Exp. Ther. 231:166–172.
Trottier, S., Berger, B., Chauvel, P., Dedek, J., and Gay, M. 1981. Alterations of the cortical noradrenergic system in chronic cobalt epileptogenic foci in the rat: A histoflourescent and biochemical study. Neuroscience 6:1069–1080.
Altamura, A. C., Bonati, M., Brunello, N., Giordano, P. L., and Algeri, S. 1987. The activities of some neurotransmitter synthesizing enzymes in experimental cobalt epilepsy. Neurosci Lett 7:83–87.
Reimann, W., Zumstein, A., Jackish, R., Starke, K., and Hertting, G. 1979. Effect of extracellular dopamine on the release of dopamine in the rabbit caudate nucleus: Evidence for a dopaminergic feedback inhibition. Naunyn. Schmiedberg. Arch. Pharmacol. 306:53–60.
Goldstein, D., Nadi, N. S., Stull, R., Wyler, A. R., and Porter, R. J. 1988. Levels of catechols in normal and epileptic regions of the human brain. J. Neurochem. 50:225–229.
Papeschi, R., Moline-Negro, P., Sourkes, T. L., and Giuseppe, E. 1972. The concentration of homovanillic acid and 5-hydroxy indole acetic acids in ventricular and lumbar cerebrospinal fluid. Neurology 22:1151–1159.
Devinsky, O., Emoto, S., Goldstein, D. S., Stull, R., Porter, R. J., Theodore, W. H., and Nadi, N. S. 1992. Cerebrospinal fluid and serum levels of dopa, catechols and monoamine metabolites in patients with epilepsy. Epilepsia 33:263–270.
Crunelli, V., Bernasconi, S., and Samanin, R. 1979. Evidence against serotonin involvement in the tonic component of electrically induced convulsions and in carbamazepine anticonvulsant activity. Psychopharmacology 66:79–85.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Meshki Baf, M.H., Subhash, M.N., Lakshmana, K.M. et al. Alterations in monoamine levels in discrete regions of rat brain after chronic administration of carbamazepine. Neurochem Res 19, 1139–1143 (1994). https://doi.org/10.1007/BF00965147
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00965147